Therefore, careful exploration of the clinical benefit of MMP-9 inhibition at low dose or a therapeutic decrease of MMP-9 levels by other methods such as by RNA silencing therapeutics for reduction of MRD in B-ALL may be a worthwhile cause. This evidence concerns the gene MMP9 and acute lymphoblastic leukemia.